Pasireotide pamoate
Pasireotide pamoate is a cyclohexapeptide somatostatin analogue administered as a long-acting release injection. It works by binding to somatostatin receptors, thereby decreasing the excess production of growth hormone, IGF-1, and ACTH.
Dosage by Body Weight
Administered exclusively by a healthcare professional as a deep intramuscular injection into the gluteal muscle once every 4 weeks. Doses range from 10 mg to 60 mg depending on the condition being treated and patient response.
- Body Weight
- Below 5 kg
- Dose
- Not established
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not established
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not established
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not established
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not established
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not established | N/A | Safety and effectiveness in pediatric patients have not been established. |
| 5-7 kg | Not established | N/A | Safety and effectiveness in pediatric patients have not been established. |
| 8-10 kg | Not established | N/A | Safety and effectiveness in pediatric patients have not been established. |
| 11-15 kg | Not established | N/A | Safety and effectiveness in pediatric patients have not been established. |
| 16-20 kg | Not established | N/A | Safety and effectiveness in pediatric patients have not been established. |
Formulation
Purpose
Treatment of adult patients with acromegaly who cannot be treated with surgery or for whom surgery has failed, and for patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.
Generic Name
Pasireotide pamoateBranded Drug Names
Pasireotide pamoate is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.